| Heading: |
Alzheimer's Disease: Drugs |
| Question ID: |
1816699 |
| UIN: |
62774 |
| House: |
Commons |
| Date tabled: |
2025-06-25 |
| Asking Member ID: |
5072 |
| Asking Member display name: |
Mr Andrew Snowden
|
| Asking Member handle: |
A_J_Snowden
|
| Asking Member Twitter reference: |
@A_J_Snowden
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 June to Question 61301 on Alzheimer's Disease: Drugs, whether NICE has made an assessment of the potential impact of not publishing the economic models for (a) lecanema |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence’s (NICE) single technology appraisal process relies on information provided by companies to evaluate the clinical and cost-effectiveness of new treatments. Some of this information, including the econo... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |